Regen BioPharma Files 10-Q for Q2 2024

TL;DR

Regen BioPharma filed its Q2 2024 10-Q, showing financial details and preferred stock info.

AI Summary

Regen BioPharma Inc. filed its 10-Q for the period ending June 30, 2024. The company's fiscal year ends on September 30th. Key financial data and preferred stock series (A, AA, M, NC) are detailed for the periods ending June 30, 2024, and September 30, 2023.

Why It Matters

This filing provides investors with an update on Regen BioPharma's financial position and operational details for the second quarter of 2024.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Regen BioPharma faces inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

• 2024-06-30 — Reporting Period End Date (Latest financial data available)
• 2023-09-30 — Prior Fiscal Year End Date (Comparison point for financial data)

Key Players & Entities

• Regen BioPharma Inc. (company) — Filer of the 10-Q
• June 30, 2024 (date) — End of reporting period
• September 30 (date) — Fiscal year end
• Series A Preferred Stock (dollar_amount) — Preferred stock series detailed
• Series AA Preferred Stock (dollar_amount) — Preferred stock series detailed
• Series M Preferred Stock (dollar_amount) — Preferred stock series detailed
• Series NC Preferred Stock (dollar_amount) — Preferred stock series detailed

FAQ

Filing Documents

• rgbp063024form10q.htm (10-Q) — 930KB
• ex31_1.htm (EX-31.1) — 9KB
• ex31_2.htm (EX-31.2) — 9KB
• ex32_1.htm (EX-32.1) — 4KB
• ex32_2.htm (EX-32.2) — 4KB
• ex10_1.htm (EX-10.1) — 3KB
• ex10_2.htm (EX-10.2) — 3KB
• 0001607062-24-000238.txt ( ) — 4195KB
• rgbp-20240630.xsd (EX-101.SCH) — 45KB
• rgbp-20240630_cal.xml (EX-101.CAL) — 41KB
• rgbp-20240630_def.xml (EX-101.DEF) — 146KB
• rgbp-20240630_lab.xml (EX-101.LAB) — 285KB
• rgbp-20240630_pre.xml (EX-101.PRE) — 239KB
• rgbp063024form10q_htm.xml (XML) — 524KB

From the Filing

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File No. 333-191725 REGEN BIOPHARMA, INC. (Exact name of small business issuer as specified in its charter) Nevada 45-5192997 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 4700 Spring Street , St 304 , La Mesa , California 91942 (Address of Principal Executive Offices) 619 722-5505 (Issuer's telephone number) None (Former name, address and fiscal year, if changed since last report) Check whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the issuer was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer," "non-accelerated Large accelerated filer Accelerated Smaller reporting company Emerging Growth Company APPLICABLE ONLY TO CORPORATE ISSUERS: As of July 17, 2024 Regen Biopharma, Inc. had 4,508,320 common shares outstanding. As of July 17, 2024 Regen Biopharma, Inc. had 10,123,771 shares of Series A Preferred Stock outstanding. As of July 17, 2024 Regen Biopharma, Inc. had 34 shares of Series AA Preferred Stock outstanding. As of July 17, 2024 Regen Biopharma, Inc. had 29,338 shares of Series M Preferred Stock outstanding. As of July 17, 2024 Regen Biopharma, Inc. had 15,007 shares of Series NC Preferred Stock outstanding. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes No 1 PART I - FINANCIAL INFORMATION Item 1. - Financial Statements REGEN BIOPHARMA , INC. CONDENSED CONSOLIDATED BALANCE SHEETS As of June 30, 2024 September 30, 2023 (unaudited) ASSETS CURRENT ASSETS Cash $ 61,849 $ 121,037 Accounts Receivable, Related Party 67,147 0 Note Receivable, Related Party 0 Prepaid Expenses 10,921 0 Prepaid Rent 12,500 10,000 Total Current Assets 152,417 131,037 OTHER ASSETS Investment Securities, Related Party 17,733 222,580 Total Other Assets 17,733 222,580 Total Assets $ 170,150 $ 353,617 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable 29,416 29,674 Notes Payable 218,230 95,710 Accrued payroll taxes 4,241 4,241 Accrued Interest 359,970 342,588 Accrued Payroll 1,256,630 1,256,630 Other Accrued Expenses 41,423 41,423 Bank Overdraft 1,000 1,000 Due to Investor 20,000 20,000 Unearned Income 1,496,811 1,591,731 Unearned Income (Related Party) 0 15,126 Derivative Liability 1,400,261 1,400,000 Convertible Notes Payable Less unamortized discount 499,880 499,880 Convertible Notes Payable, Related Parties Less unamortized discount 0 10,000 Total Current Liabilities 5,327,862 5,308,003 Long Term Liabilities: Convertible Notes Payable, Related Parties Less unamortized discount Notes Payable 0 149,614 Total Long Term Liabilities 0 149,614 Total Liabilities 5,327,862 5,457,617 STOCKHOLDERS' EQUITY (DEFICIT) Common Stock ($ .0001 par value) 500,000,000 shares authorized; 5,800,000,000 authorized and 4,373,078 issued and outstanding as of June, 2024 and 3,506,366 shares issued and outstanding as of September 30, 2023. 439 352 Preferred Stock, 0.0001 par value, 800,000,000 authorized as of June 30, 2024 and September 30, 2023 respectively Series A Preferred; 739,000,000 authorized as of September 30, 2023 and June 30, 2024; 429,619 outstanding as of June 30, 2024 and 409,551 outstanding as of September 30, 2023 42 40 Series AA Preferred; $ 0.0001 par value 600,000 authorized and 34 and 34 outstanding as of June 30, 2024 and September 30,2023 respectively 0 0 Series M Preferred; $ 0.0001 par value 60,000,000 authorized and 29,338 outstanding as of September 30, 2023 and 60,000,000 authorized and 29,338 outstanding as of June 30, 2024 3 3 Series NC Preferred; $ 0.0001 par value 20,000 authorized and 15,007 outstanding as of September 30, 2023 and

View Full Filing

View this 10-Q filing on SEC EDGAR